Pages that link to "Q39965021"

The following pages link to CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice (Q39965021):

Displaying 46 items.

• The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease (Q22306292) (← links)
• Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II. (Q27005950) (← links)
• Mutant Huntingtin Alters Cell Fate in Response to Microtubule Depolymerization via the GEF-H1-RhoA-ERK Pathway (Q28576523) (← links)
• Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease (Q28743929) (← links)
• IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. (Q30435758) (← links)
• Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes (Q30536567) (← links)
• Detection of Mutant Huntingtin Aggregation Conformers and Modulation of SDS-Soluble Fibrillar Oligomers by Small Molecules (Q30547549) (← links)
• Targeting protein kinases in central nervous system disorders (Q33671660) (← links)
• Huntington's disease: from molecular pathogenesis to clinical treatment (Q33773061) (← links)
• Brain-derived neurotrophic factor in patients with Huntington's disease (Q33999072) (← links)
• BDNF signaling and survival of striatal neurons (Q34102098) (← links)
• BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases (Q34344683) (← links)
• ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease (Q34424253) (← links)
• Targets for future clinical trials in Huntington's disease: what's in the pipeline? (Q34435001) (← links)
• Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. (Q34440282) (← links)
• Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice (Q34459323) (← links)
• Huntington's Disease and Striatal Signaling. (Q35286098) (← links)
• Oxidative stress in neurodegenerative diseases: mechanisms and therapeutic perspectives (Q35608958) (← links)
• Cellular therapy and induced neuronal replacement for Huntington's disease. (Q35648164) (← links)
• Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease (Q35782283) (← links)
• Loss of MLK3 signaling impedes ulcer healing by modulating MAPK signaling in mouse intestinal mucosa (Q36312697) (← links)
• Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models (Q36538885) (← links)
• Impaired TrkB Signaling Underlies Reduced BDNF-Mediated Trophic Support of Striatal Neurons in the R6/2 Mouse Model of Huntington's Disease (Q36665616) (← links)
• A TrkB small molecule partial agonist rescues TrkB phosphorylation deficits and improves respiratory function in a mouse model of Rett syndrome (Q37008339) (← links)
• MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition (Q37012789) (← links)
• Targeting H3K4 trimethylation in Huntington disease (Q37088721) (← links)
• Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. (Q37313530) (← links)
• A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease (Q37345118) (← links)
• An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders (Q37733587) (← links)
• Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease (Q37776087) (← links)
• Molecular biomarkers of lung carcinoma (Q37971659) (← links)
• Herbal therapeutics that block the oncogenic kinase PAK1: a practical approach towards PAK1-dependent diseases and longevity (Q38128777) (← links)
• Neurotrophin strategies for neuroprotection: are they sufficient? (Q38194485) (← links)
• Potential therapeutic targets in polyglutamine-mediated diseases (Q38246221) (← links)
• Huntington's disease: Molecular basis of pathology and status of current therapeutic approaches (Q38815118) (← links)
• Neuropharmacologic Approaches to Restore the Brain's Microenvironment. (Q38879533) (← links)
• Humanized mice: models for evaluating NeuroHIV and cure strategies (Q40074303) (← links)
• Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes (Q42714345) (← links)
• Identification of anti-inflammatory targets for Huntington's disease using a brain slice-based screening assay (Q42741104) (← links)
• Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington's disease delays the onset of the motor phenotype (Q45303314) (← links)
• Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington's Disease (Q47280331) (← links)
• Sustained Gq-Protein Signaling Disrupts Striatal Circuits via JNK. (Q47393947) (← links)
• Marine-derived protein kinase inhibitors for neuroinflammatory diseases. (Q52565796) (← links)
• Early Downregulation of p75NTR by Genetic and Pharmacological Approaches Delays the Onset of Motor Deficits and Striatal Dysfunction in Huntington's Disease Mice. (Q54978077) (← links)
• Huntington disease (Q56083219) (← links)
• The role of Twist1 in mutant huntingtin-induced transcriptional alterations and neurotoxicity (Q56770267) (← links)